All In Biotech

Drug Trial Radar · NCT04223193

Flexible-Dose Trial in Early Parkinson's Disease (PD)

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson's Disease (TEMPO-2 Trial)

Last checked: Nov 19, 2026Latest source record: Nov 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 304 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

304

Actual

Start

Jan 6, 2020

Primary completion

Oct 1, 2024

Study completion Oct 1, 2024

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Jan 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy, safety, tolerability and pharmacokinetics (PK) of flexible doses of tavapadon in participants with Parkinson's Disease.

Conditions

  • Parkinson Disease

Interventions

  • TavapadonDrug

    Participants will be randomized to receive tavapadon 5 mg QD to 15 mg QD tablet once daily orally for 27 weeks.

  • PlaceboDrug

    Participants will receive placebo matching to tavapadon QD orally for 27 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III Combined ScoreTime frame: Week 26

Locations

53 sites in 13 countries. Site status is shown where the registry gives one.

  • Fresno, California

    Fresno, California

  • Boca Raton, Florida

    Boca Raton, Florida

  • Maitland, Florida

    Maitland, Florida

  • Ocala, Florida

    Ocala, Florida

  • Winter Park, Florida

    Winter Park, Florida

  • Boston Neuro Research Center

    North Dartmouth, Massachusetts

  • Albany, New York

    Albany, New York

  • Syracuse, New York

    Syracuse, New York

  • Cincinnati, Ohio

    Cincinnati, Ohio

  • Cleveland, Ohio

    Cleveland, Ohio

  • Memphis, Tennessee

    Memphis, Tennessee

  • Cypress, Texas

    Cypress, Texas

  • Houston, Texas

    Houston, Texas

  • Lubbock, Texas

    Lubbock, Texas

  • Round Rock, Texas

    Round Rock, Texas

  • Richmond, Virginia

    Richmond, Virginia

  • Richmond, Virginia

    Richmond, Virginia

  • Kirkland, Washington

    Kirkland, Washington

  • Macquarie Park, New South Wales

    Sydney, New South Wales, Australia

  • Marseille, France

    Marseille, France, France

  • Nantes CEDEX 1

    Nantes, Nantes, France

  • Toulouse Cedex 9

    Toulouse, Toulouse, France

  • Bochum

    Bochum, Bochum, Germany

  • Gera

    Gera, Gera, Germany

  • Muenchen

    München, Muenchen, Germany

  • Berlin

    Berlin, State of Berlin, Germany

  • Tatabanya

    Tatabánya, Hungary

  • Budapest

    Budapest, Budapest, Hungary

  • Pecs

    Pécs, Hungary, Hungary

  • Rozzano Milano

    Rozzano, Italy

  • Torino

    Torino, Italy

  • Cassino

    Cassino, Cassino, Italy

  • Milano

    Milan, Milano, Italy

  • Rome

    Rome, Rome, Italy

  • Centrum Medyczne NEUROMED

    Bydgoszcz, Poland

  • Centrum Medyczne Hope Clinic Sebastian Szklener

    Lublin, Poland

  • Cracow

    Krakow, Cracow, Poland

  • Katowice

    Katowice, Katowice, Poland

  • Siemianowice Slaskie

    Siemianowice Śląskie, Siemianowice Slaskie, Poland

  • Belgrade

    Belgrade, Belgrade, Serbia

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.